Innovent Biopharmaceutical Transformation
Anticipated Milestones in 2022
Regulatory
Actions
Regulatory
Filings
New Phase 3
/Pivotal studies
Key PoC
readouts
PoC/Phase 2
data release
First-in-human
assets
⚫TYVYTⓇ (PD-1): 1L GC
• TYVYTⓇ (PD-1): 1L ESCC
⚫ IBI326 (BCMA CAR-T): MM
⚫ IBI306 (PCSK9): nFH
• IBI188 (CD47): 1H2022, MDS
⚫ IBI110 (LAG3): 1H2022
• TYVYT® (PD-1): EGFRM
NSCLC
⚫ IBI306 (PCSK9): HeFH
⚫IBI310 (CTLA-4): CC
⚫ IBI362 (OXM3): 2H2022,
Obesity
⚫IBI362 (OXM3): 2H2022,
Diabetes
• IBI322 (CD47/PDL1):
2H2022
• IBI110 (LAG-3)
• IBI351 (KRAS): 1H2022
• IBI322 (CD47/PDL1)
• RETSEVMO® (RET): NSCLC
• IBI939 (TIGIT): 1H2022
⚫ IBI376 (PI3K8): FL*
⚫ RETSEVMO® (RET): MTC
• IBI112 (IL-23): 2H2022,
Psoriasis
⚫ IBI351 (KRAS)
• IBI323 (PD-L1/LAG3):
2H2022
⚫ IBI939 (TIGIT)
• RETSEVMO® (RET): TC
• IBI351 (KRAS): 2H2022,
NSCLC
• CYRAMZAⓇ (VEGF): HCC
PemazyreⓇ: mCCA
(mainland China)
• BYVASDAⓇ : Indonesia
• IBI188 (CD-47): 1H2022, MDS
• IBI310 (CTLA-4)
• IBI362 (OXM3): Diabetes;
Obesity
• IBI112 (IL-23): Psoriasis
• IBI363 (PD-1/IL-2)
⚫ IBI389 (CLDN18.2/CD3)
⚫ IBI325 (CD73)
⚫ IBI333 (VEGF-A/VEGF-C)
• IBI324 (VEGF/ANG-2)
⚫ IBI311 (IGF-1R)
⚫ IBI353 (PDE4)
• IBI346 (CLDN18.2 CAR-T)
⚫ IBI343 (CLDN18.2 ADC)
• More including ADC, cell
therapy, Ab, multispecific
antibodies, etc.
*Note: We plan to have communication with China NMPA regarding the potential submission of PI3K8. Incyte has
withdrawn the application of parsaclisib in FL, MZL and MCL in the U.S. as a business decision and is not related to
any changes in either the efficacy or safety of parsaclisib.
Innovent
Confidential
Copyright©2022 Innovent
22
22View entire presentation